Skye Bioscience Capital Expenditures (CapEx) Growth & History (SKYE)
Skye Bioscience's capital expenditures (capex) was $6,312 for fiscal 2025.
View full Skye Bioscience company overviewSkye Bioscience annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6,312 | −$1.6M | −99.61% |
| 2024 | 2024-12-31 | $1.6M | $1.6M | +12681.09% |
| 2023 | 2023-12-31 | $12,550 | −$15,510 | −55.27% |
| 2022 | 2022-12-31 | $28,060 | −$62,806 | −69.12% |
| 2021 | 2021-12-31 | $90,866 | $83,636 | +1156.79% |
| 2020 | 2020-12-31 | $7,230 | — | — |
| 2018 | 2018-12-31 | $4,385 | −$15,269 | −77.69% |
| 2017 | 2017-12-31 | $19,654 | $8,537 | +76.79% |
| 2016 | 2016-12-31 | $11,117 | $9,135 | +460.90% |
| 2015 | 2015-12-31 | $1,982 | −$21,280 | −91.48% |
| 2014 | 2014-12-31 | $23,262 | — | — |
| 2013 | 2013-10-31 | $49,116 | — | — |
Skye Bioscience quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | −$6,312 | — |
| Q4 2025 | 2025-12-31 | $0 | −$50,024 | — |
| Q3 2025 | 2025-09-30 | $0 | −$1.5M | — |
| Q2 2025 | 2025-06-30 | $0 | −$32,463 | — |
| Q1 2025 | 2025-03-31 | $6,312 | $3,131 | +98.43% |
| Q4 2024 | 2024-12-31 | $50,024 | $43,007 | +612.90% |
| Q3 2024 | 2024-09-30 | $1.5M | $1.5M | +41238.39% |
| Q2 2024 | 2024-06-30 | $32,463 | $32,463 | — |
| Q1 2024 | 2024-03-31 | $3,181 | $1,321 | +71.02% |
| Q4 2023 | 2023-12-31 | $7,017 | −$5,487 | −43.88% |
| Q3 2023 | 2023-09-30 | $3,673 | −$6,671 | −64.49% |
| Q2 2023 | 2023-06-30 | $0 | −$3,213 | — |
| Q1 2023 | 2023-03-31 | $1,860 | −$139 | −6.95% |
| Q4 2022 | 2022-12-31 | $12,504 | −$41,534 | −76.86% |
| Q3 2022 | 2022-09-30 | $10,344 | −$16,314 | −61.20% |
| Q2 2022 | 2022-06-30 | $3,213 | $2,687 | +510.84% |
| Q1 2022 | 2022-03-31 | $1,999 | −$8,697 | −81.31% |
| Q4 2021 | 2021-12-31 | $54,038 | $46,808 | +647.41% |
| Q3 2021 | 2021-09-30 | $26,658 | $26,658 | — |
| Q2 2021 | 2021-06-30 | $526 | $526 | — |
| Q1 2021 | 2021-03-31 | $10,696 | $10,696 | — |
| Q4 2020 | 2020-12-31 | $7,230 | — | — |
| Q2 2020 | 2020-09-30 | $0 | — | — |
| Q1 2020 | 2020-06-30 | $0 | — | — |
| Q4 2019 | 2020-03-31 | $0 | — | — |
| Q4 2018 | 2018-12-31 | $0 | — | — |
| Q3 2018 | 2018-09-30 | $0 | — | — |
| Q2 2018 | 2018-06-30 | $3,326 | — | — |
| Q1 2018 | 2018-03-31 | $1,059 | — | — |
| Q4 2016 | 2016-12-31 | $1 | — | — |
| Q3 2016 | 2016-09-30 | $0 | — | — |
| Q2 2016 | 2016-06-30 | $0 | — | — |
| Q1 2016 | 2016-03-31 | $11,116 | — | — |
| Q4 2013 | 2013-10-31 | $0 | — | — |
| Q3 2013 | 2013-07-31 | $0 | — | — |
| Q2 2013 | 2013-04-30 | $1,645 | — | — |
| Q1 2013 | 2013-01-31 | $47,471 | — | — |
Skye Bioscience capital expenditures (capex) trends
Over the last five fiscal years, Skye Bioscience's capital expenditures (capex) decreased from $7,230 to $6,312, a change of −$918. The latest reported quarter, Q2 2026, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Skye Bioscience source filings ↗